Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375424" target="_blank" >RIV/00216208:11130/18:10375424 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/18:10375424
Result on the web
<a href="https://doi.org/10.1080/2162402X.2018.1433982" target="_blank" >https://doi.org/10.1080/2162402X.2018.1433982</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2018.1433982" target="_blank" >10.1080/2162402X.2018.1433982</a>
Alternative languages
Result language
angličtina
Original language name
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
Original language description
Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant anticancer immune responses has attracted considerable attention. However, only three cytokines have been approved so far by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, namely, recombinant interleukin (IL)-2 and two variants of recombinant interferon alpha 2 (IFN-2 and IFN-alpha 2b). Moreover, the use of these cytokines in the clinics is steadily decreasing, mostly as a consequence of: (1) the elevated pleiotropism of IL-2, IFN-alpha 2a and IFN-alpha 2b, resulting in multiple unwarranted effects; and (2) the development of highly effective immunostimulatory therapeutics, such as immune checkpoint blockers. Despite this and other obstacles, research in the field continues as alternative cytokines with restricted effects on specific cell populations are being evaluated. Here, we summarize research preclinical and clinical developments on the use of recombinant cytokines for immunostimulation in cancer patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
OncoImmunology [online]
ISSN
2162-402X
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
16
Pages from-to
—
UT code for WoS article
000432214900019
EID of the result in the Scopus database
2-s2.0-85046862171